Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nuvectis Pharma, Inc. - Common Stock (NQ:NVCT)

6.360 -0.350 (-5.22%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nuvectis Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Nuvectis Pharma Announces Upcoming Poster Presentation for NXP800 at the 2023 AACR Special Conference on Endometrial Cancer
From Nuvectis Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Nuvectis Pharma Announces Updated Date and Time for the 2023 Cantor Global Healthcare Conference Corporate Presentation
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma: Q1 Earnings Insights
 
Via Benzinga
Nuvectis Pharma Announces Upcoming Presentations for NXP800 and NXP900
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Initiation of the NXP900 Phase 1a Clinical Trial
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma to Host KOL Event to Discuss Its Two Precision Medicine Clinical-Stage Drug Candidates, NXP800 and NXP900
Virtual Event to be held on Thursday, September 14, 2023 at 10:00 a.m. ET 
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA to NXP800 for the Treatment of Cholangiocarcinoma
From Nuvectis Pharma, Inc.
Via GlobeNewswire
10 Short Squeeze Stocks To Watch: Blue Apron, Intuitive Machines, Yellow Corp, Getty Images And More
Potential short squeeze plays gained steam in 2021, continued throughout 2022, and remain a new focus of traders looking for the next huge move. High short interest and steep borrowing costs are among... 
Via Benzinga
Insiders Buying Texas Capital Bancshares And 3 Other Stocks
Although U.S. stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
Insiders Buying Steel Connect And 2 Other Stocks
Although US stocks closed mixed on Thursday, there were a few notable insider trades. 
Via Benzinga
Insiders Buying Nuvectis Pharma And 2 Other Stocks
Although US stocks closed mostly higher on Wednesday, there were a few notable insider trades. 
Via Benzinga
Insiders Buying Joint Corp And 2 Other Stocks
Although US stocks closed higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
Insiders Buying BranchOut Food And 2 Other Stocks
Although US stocks closed higher for the fourth session in a row, there were a few notable insider trades. 
Via Benzinga
Insiders Buying Asana And 2 Other Stocks
When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.... 
Via Benzinga
More Than $3M Bet On Asana? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed higher on Monday, there were a few notable insider trades. 
Via Benzinga
$1M Bet On Children's Place? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Thursday, there were a few notable insider trades. 
Via Benzinga
Nuvectis Pharma Set to Join the Russell 2000® and Russell 3000® Indexes
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Over $2M Bet On This Financial Services Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Friday, there were a few notable insider trades. 
Via Benzinga
Nuvectis Pharma Announces FDA Clearance of NXP900 IND
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Correction: Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800's Activity in Cholangiocarcinoma PDX Models at the 2023 American Association for Cancer Research (“AACR”) Annual Meeting
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Initiation of the Phase 1b Study for NXP800 in Platinum-Resistant, ARID1a-Mutated Ovarian Carcinoma
Phase 1b study builds on highly consistent preclinical and Phase 1a data 
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Upcoming Presentations at the 2023 American Association for Cancer Research Meeting
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma to Participate in a Fireside Chat at the 35th Annual Roth Conference
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Recaps Poster Presentation Highlights for NXP800 at the 2023 ESMO Gynecological Cancers Congress
Treatment with NXP800 resulted in substantial tumor growth inhibition in two in vivo xenograft models of ARID1a-mutated ovarian carcinoma, superior to treatment with cisplatin 
From Nuvectis Pharma, Inc.
Via GlobeNewswire
Nuvectis Pharma Announces Collaboration with ENGOT and GOG Foundation to Conduct the NXP800 Phase 1b Clinical Trial in ARID1A-Mutated Ovarian Carcinoma in Europe and in the United States
From Nuvectis Pharma, Inc.
Via GlobeNewswire
FDA Grants Fast Track Designation to Nuvectis Pharma's NXP800 for the Treatment of Platinum-Resistant, ARID1A-Mutated Ovarian Carcinoma
From Nuvectis Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.